Stocks · News reference

Elutia To Sell SimpliDerm Business To Cellution Biologics For Up To $11M

Jul 16, 2026, 8:06 PMBenzinga Newsdesk

Reference details

Connected markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Keep reading

SEC EDGARAug 21, 2026, 9:00 PMSEC EDGAR
8-K filing — ELUTIA INC. (ELUT)
Filed: 2026-08-21 AccNo: 0001104659-26-099731 Size: 644 KB Item 2.01: Completion of Acquisition or Disposition of Assets Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
Read original at edgar
ELUT
BenzingaAug 13, 2026, 10:00 PMBenzinga Insights
Elutia Q2 2026 Earnings Call Transcript
On Thursday, Elutia (NASDAQ:ELUT) discussed second-quarter financial results during its earnings call. The full transcript is provided below. This transcript is brought to you by Benzinga APIs. For real-time access to
Read original at benzinga
ELUT
BenzingaAug 13, 2026, 8:33 PMBenzinga Newsdesk
Elutia Secures Up To $26M Of Additional Capital To Support NXT-41x Clearance And Its First Full Year Of Commercial Launch In 2028
Funded through launch: secured up to $26 million of capital without an equity offeringThe unmet need is real: 86% of surgeons surveyed say the matrices they use today increase infection riskThe demand is strong: 96% of
Read original at benzinga
ELUT
BenzingaAug 13, 2026, 8:11 PMBenzinga Newsdesk
Elutia Q2 EPS $(0.17) Misses $(0.15) Estimate, Sales $2.427M Miss $2.900M Estimate
Elutia (NASDAQ:ELUT) reported quarterly losses of $(0.17) per share which missed the analyst consensus estimate of $(0.15) by 13.33 percent. This is a 34.62 percent increase over losses of $(0.26) per share from the
Read original at benzinga
ELUT